Treats pulmonary arterial hypertension (PAH) (WHO Group 1). ANDA 210715, held by Cipla. Ambrisentan.
As of Nov 21, 2026, ANDA 210715 (Ambrisentan), held by Cipla, was first approved by FDA on Apr 26, 2019, with 7 approved supplements and 0 published complete response letters.
Ambrisentan tablets are indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in adult patients: To improve exercise ability and delay clinical worsening. Studies establishing effectiveness included predominantly patients with WHO Functional Class II–III symptoms and etiologies of idiopathic or heritable PAH (60%) or PAH associated with connective tissue diseases (34%).
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 26, 2019 | Original application | Approved |
| Ambrisentan5MG · tablet;oral | Ambrisentan | Rx |
| Ambrisentan10MG · tablet;oral | Ambrisentan | Rx |
| Apr 4, 2025 | Supplement 10REMS | Approved | None posted |
| Aug 19, 2024 | Supplement 9REMS | Approved | None posted |
| Jun 8, 2021 | Supplement 6REMS | Approved | None posted |
| Dec 22, 2020 | Supplement 4REMS | Approved | None posted |
| Apr 20, 2020 | Supplement 2REMS | Approved | None posted |
| Feb 14, 2020 | Supplement 3Labeling · Standard review | Approved | None posted |
| Nov 6, 2019 | Supplement 1Labeling · Standard review | Approved | None posted |
| Apr 26, 2019 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters